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INTRODUCTION

Sickle cell disease (SCD) is a rare inherited disorder that affects the shape of erythrocytes.
SCD is estimated to affect 70,000 - 100,000 Americans and is seen predominately in
African-Americans.1 In SCD, the body produces sickle-shaped red blood cells, which have
shorter lifespans than normal red blood cells and can lead to anemia. The abnormal shape
causes them to become lodged in blood vessels, causing pain and organ damage. Symptoms
generally begin by three years of age and complications of sickle cell disease include vasoocclusive crises, acute chest syndrome, and others.2 A vaso-occlusive crisis is an episode of
pain, described as sharp, intense, and throbbing, most commonly occurring in the lower
back, leg, hip, abdomen, or chest. It typically begins at night and lasts 3-14 days. It is the
most common reason for hospitalization in patients with SCD.3 Episodes increase in
frequency throughout childhood.4 No cure for SCD is widely available; treatment is
symptomatic and supportive. No evidence based guidelines for the treatment of pain during
vaso-occlusive crises in pediatric patients with SCD are published.3

RESULTS
• A comprehensive literature search provided 1,094 results, including duplicate results
• Screening of the literature search results identified 16 trials that needed further evaluation
• Six trials were included in the systematic review, after application of the inclusion and exclusion
criteria. Studies are summarized in Figure 3 and Table 1.
• Many studies were excluded resulting from lack of rigor in study design or missing results.
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Figure 3. Summary of included trials
Includes intervention studied and sample size

PURPOSE
The purpose of this literature review was to evaluate the safety and efficacy data of selected
trials, provide a summary of evidence-based treatments, and identify specific areas where
more studies are needed in the treatment of vaso-occlusive crises in pediatric patients.

Name of trial

Pain Scale

Outcome Measure

Results

Safety

Fein, et al.6

Wong-Baker
FACES

Median reduction in
pain score 20 minutes
after drug
administration

Pain score was reduced by 2
in the IN fentanyl group vs.
1 in the placebo group
(p=0.048) 20 minutes after
drug administration. No
significant difference was
seen at 10 or 30 minutes

No significant
difference in
serious adverse
effects

The difference in mean VAS
scores at 24 hours or the
change from baseline was
not significant between
groups.

No significant
difference in
serious adverse
effects

METHODOLOGY
Studies were included in the review if they were randomized controlled trials. Trials must
include participants 18 years and younger with sickle cell disease. The intervention must be
an FDA approved medication (not necessarily approved for SCD). One of the outcomes
measured in the trial must be reduction in pain score; no standard pain score exists so
different scores will be included (Wong-Baker FACES Pain Rating Scale, Visual Analog
Scale, etc. See Figure 1 and Figure 2). Secondary outcomes include serious adverse events.
Studies were evaluated for rigor using the JADAD score, and were included if the score was
≥ 3.
Literature searches were conducted using PubMed, Embase, Cochrane Central Register,
and ClinicalTrials.gov. Search terms included (but were not limited to): “sickle cell
disease”, “sickle cell crisis”, “vaso-occlusive crisis”, “pain management”, “analgesia”,
“opioid”, “non-opioid”, “NSAID”, “pediatric”, and “children”.

Figure 1. Wong-Baker FACES Pain Rating Scale
Recommended for children three years and older. Child is asked to choose the
face that best describes his/her own pain.5

Figure 2. Visual Analog Scale
Patients are asked to rate pain on a
10 cm line and the distance from no
pain is considered the pain score.5

Gladwin, et al.7

Weiner, et al. 8

Visual Analog
Scale

Pain score at 24 hours,
and change from
baseline at 2, 4, 6, and
8 hours

Visual Analog
Scale

Difference in pain
The difference in pain
scores at 4 hours from scores at 4 hours was not
baseline
statistically significant
between the two groups.

No serious
adverse events
were seen in
either group

The difference in mean and
median pain scores was not
significant between the two
groups.

Infusion site
reactions were
more common in
IV MgSO4 group

Hardwick, et al.10 Visual Analog
Scale

Reduction in pain
severity (VAS score)

The reduction in pain
severity did not differ
significantly between the
two groups.

No significant
difference in
serious adverse
events

Morris, et al.11

Pain scores at
discharge

There was a significant
No drug-related
difference in pain scores at adverse events in
discharge (1.9 L-arginine vs. either group
3.9 placebo, p < 0.001)

Table 1. Summary of included trials
Six trials were reviewed for safety and efficacy data.

A strength of this study is limited inclusion criteria to allow for as many trials to be
included as possible. The literature search was comprehensive and complete. Weaknesses
include the small sample sizes in trials, differences in pain scales used, and differences in
the time periods in which pain was measured during the crisis. Each trial measured pain
scores at different points throughout treatment, and it is difficult to compare and
generalize the different results. Limited published trials exist that are controlled clinical
trials with strong designs.

CONCLUSIONS
Based on the results of the literature review, intranasal fentanyl and L-arginine have some
evidence for use in pediatric patients with vaso-occlusive crises. More evidence is needed;
however both may be reasonable, safe options in patients with uncontrolled pain as an
adjunct to standard therapy.

Goldman, et al.9 Faces Pain Scale Mean pain score
– Revised,
Visual Analog
Scale

Visual Analog
Scale, Faces
Pain Scale

Of the six studies analyzed, two showed statistical significance in the decrease in pain scores
in children with vaso-occlusive crises. The Fein trial showed a significant reduction in pain
score at 20 minutes after the administration of intranasal fentanyl. The difference was seen
at 20 minutes after administration, but not 10 or 30 minutes. The Morris trial showed a
significant difference in pain scores at discharge in patients in the arginine arm. The other
studies did not show statistical significance, however the small sample size of the trials only
had the power to detect large changes in outcomes. Another consideration is the difference
between clinical significance and statistical significance. While the trials may not have had
a statistical difference in pain scores, the differences may have been enough to show clinical
improvements in patients. No serious adverse effects were seen in any of the trials.

Trials are needed with larger sample sizes to detect a smaller change in outcomes. It would
be beneficial if trials used a standard pain scale, easing the comparison between trials.
Studies in this population are difficult because of the subjectivity of endpoints, such as pain
and length of stay. Length of stay may be influenced by many non-treatment related factors
(e.g. discharge paper work), although it was included in many of the reviewed trials as a
primary or secondary outcome. Future reviews may evaluate the efficacy of medication for
vaso-occlusive crises based on different outcome measures. The ethical concerns of

studying medications in children, the lack of incentives for studying rare diseases, and
the subjectivity of pain make studying the management of vaso-occlusive crises in
pediatric patients very difficult, however this review provides information regarding
safe and effective, evidence-based treatments for pediatric patients with vasoocclusive pain.
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